Completed PHASE2/PHASE3 INTERVENTIONAL NCT00121069

Study of Escitalopram in the Treatment of Specific Phobia

Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia

Sponsor: Connor, Kathryn M., M.D.

Updated 5 times since 2017 Last updated: Jul 19, 2005 Started: Sep 30, 2002 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Phobic Disorders, this trial is completed. The trial is conducted by Connor, Kathryn M., M.D. and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Connor, Kathryn M., M.D.
Forest Laboratories

Data source: Connor, Kathryn M., M.D.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States